Skip to content
glp1.howSign in

Talking to a pharmacist about compounded medications and sourcing

If you're considering or already using a compounded GLP-1, your pharmacist can help you check whether a source is legitimate and safe. Here are six questions to ask and what a good answer sounds like.

Updated Sep 26, 2026Evidence-backed

If you're using or considering a compounded GLP-1, the pharmacist is the one person in the chain whose job is to know where the product came from and how it was made. A handful of direct questions can tell you a lot about whether a source is legitimate.

Why ask a pharmacist

A pharmacist at a compounding pharmacy, or at your regular retail counter, knows how drugs are sourced and what quality standards apply, and you can usually just walk up and ask. That matters because legitimate compounding and the unregulated grey market can look alike from the outside; our guide on the compounding pharmacy debate covers where the line sits. If you want the background first, how compounded GLP-1 medications are made walks through the process step by step.

Six questions to ask

  • "Are you a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, and do you follow USP <797> for sterile preparations?"
  • "How is dosing accuracy verified for compounded products here?"
  • "Where does the active ingredient come from? Is it from an FDA-registered facility?"
  • "Is this semaglutide base, or a sodium or acetate salt form?" (FDA has said the salt forms are different active ingredients from the approved drug, with no lawful basis for use in compounding.)
  • "If I'm currently getting this from another provider, how would I know whether it's legitimate or grey-market?"
  • "What would you expect to see on a legitimate compounded product's label and packaging?"

What a good answer sounds like

Take the sourcing and salt questions. A clear answer is something like: "It's semaglutide base, made by an FDA-registered manufacturer, and we have the certificate of analysis for that batch." This is also a legal requirement: federal law requires the bulk drug substances a 503A pharmacy compounds with to come from an FDA-registered establishment and to arrive with a valid certificate of analysis. If the pharmacy can't tell you which form it uses or who made it, treat that as a warning.

Red flags to raise directly

If you're unsure about a source, ask your pharmacist to help you assess it, and name the specific concerns: no clear licensing information, prices far below other compounding pharmacies, no requirement for a valid prescription, or an ingredient that comes from outside standard pharmaceutical supply chains. You can also run the checks yourself. Our guide to verifying a pharmacy with BeSafeRx, NABP, and your state board covers the free lookups.

This is general education, not medical advice. Decisions about sourcing and your treatment belong with you, your pharmacist, and your care team.

pharmacistcompoundingconversations

Was this helpful?

Common questions

Questions people often ask about this topic.

  • What should I ask a pharmacist about a compounded GLP-1?

    Ask whether the pharmacy is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility and whether it follows USP <797> for sterile preparations. Ask how it verifies dosing accuracy, where the active ingredient comes from (ideally an FDA-registered facility), and whether the product is semaglutide base or a salt form. It's also worth asking what a legitimate compounded product's label and packaging should look like, so you have a reference point for anything you receive.

  • Can my regular retail pharmacist help, or do I need a compounding pharmacy?

    Either can help. A pharmacist at a compounding pharmacy or at your regular retail counter knows how drugs are sourced and what quality standards apply, and you can usually ask without an appointment. Ask directly instead of guessing at a product's legitimacy on your own.

  • What red flags should I raise with a pharmacist about a source I'm unsure of?

    Ask your pharmacist to help you assess the source and name specific concerns: no clear licensing information, prices far below other compounding pharmacies, no requirement for a valid prescription, or an ingredient from outside standard pharmaceutical supply chains. If you're already using another provider, you can also ask how you'd tell a legitimate source from a grey-market one.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

3Supporting

  • FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (external link)

    U.S. Food and Drug Administration · Clinical guideline · Strong evidence

    (2026)

    FDA's consumer-facing summary of compounded and unapproved GLP-1 risks: dosing errors from vials, semaglutide salt forms as different active ingredients with no lawful basis for compounding, telehealth red flags, and advice not to use product that arrives warm — the basis for the questions in this guide.

  • BeSafeRx: Your Source for Online Pharmacy Information (external link)

    U.S. Food and Drug Administration · Clinical guideline · Moderate evidence

    (2026)

    FDA consumer campaign for safely buying prescription medicine online, including a state-licensed pharmacy locator that hands off to NABP — the vetting resource behind the red-flag list here.

  • 21 U.S.C. 353a — Pharmacy compounding (FD&C Act section 503A) (external link)

    Legal Information Institute (Cornell Law School) · Clinical guideline · Strong evidence

    (2026)

    Subsection (b)(1)(A): bulk drug substances used in 503A compounding must be manufactured by an establishment registered under section 510 (21 U.S.C. 360) and be accompanied by valid certificates of analysis. Basis for the 'good answer' example.

Revision history

Last updated · 4 revisions recorded.

Show what changed
  1. v4

    Evidence sources 2 → 3

  2. v3

    Common questions revised

  3. v2

    Summary rewritten; Body revised

  4. v1

    Existing article recorded at the start of version history

Improve this page

Community notes

Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.

Loading notes…

    New submissions are currently paused. Existing approved notes remain available.

    Related terms

    • Semaglutide salt forms — Versions of semaglutide such as semaglutide sodium and semaglutide acetate, which the FDA says are different active ingredients from the semaglutide base used in approved drugs, with no known lawful basis for compounding.
    • API (active pharmaceutical ingredient) — The raw drug substance in a medication that produces its effect — for example, semaglutide itself, before it is formulated into a pen or vial.
    • Certificate of analysis (CoA) — A document reporting the lab test results for a specific batch of a drug ingredient or product, such as identity, purity, and contaminants.
    • USP <797> — The United States Pharmacopeia standard for sterile compounding that traditional 503A pharmacies must follow when preparing injectable medications.
    • Enforcement discretion — The FDA's decision to temporarily not take action against conduct that technically violates the rules, such as the grace periods it gave compounders after the GLP-1 shortages ended.

    Related guides

    • How compounded GLP-1 medications are made — and how that differs from the branded pens — A compounded GLP-1 is mixed from raw active ingredient at a pharmacy; it does not come off a branded production line. This guide explains how the drug substance is sourced, how the formula and dose are set, how a sterile compounding pharmacy makes the vial, and how that compares with the tightly controlled, FDA-approved process behind Ozempic, Wegovy, and Zepbound.